Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
波士頓，2024年12月3日（環球新聞通訊） -- Praxis Precision Medicines（納斯達克：PRAX），一家臨床階段的生物製藥公司，正在將基因洞察轉化爲針對中樞神經系統（CNS）疾病的治療開發，這類疾病的特徵是神經元興奮-抑制失衡，今天宣佈將在2024年12月參加兩場即將舉辦的投資者會議。
- Praxis management will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference, taking place in New York, NY at the Lotte New York Palace Hotel on December 4, 2024 at 2:00pm ET. A live webcast of the event will be available through this link.
- Praxis management will also be participating in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts" at the Oppenheimer Movers in Rare Disease Summit, taking place in New York, NY at the Westin Grand Central Hotel on December 12, 2024 at 2:00pm ET.
- praxis管理層將參加派傑投資第36屆年度醫療保健會議的爐邊聊天，該會議將於2024年12月4日下午2:00在紐約市的紐約樂天酒店舉行。該活動的現場直播將通過此鏈接提供。
- praxis管理層還將參加在2024年12月12日下午2:00於紐約市的西雅圖萬豪酒店舉行的"來自罕見疾病公司的電梯推介，具有關鍵的短期潛在股市推動催化劑"專題小組討論。
The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective Piper Sandler and/or Oppenheimer representatives to request meetings.
公司將在這些會議期間提供一對一的會議。感興趣的投資者應聯繫各自的派傑投資和/或奧本海默代表以請求會議。
The Piper Sandler live webcast will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website at . Following the event, a replay will be posted, when available, to Praxis' website on the "Events and Presentations" page under the investor section of the website for 90 days.
派傑投資的直播網絡研討會也將在公司網站投資者和媒體部分的「即將到來和最近的活動」頁面上提供。活動結束後，回放將在可用時發佈到praxis precision medicines的網站的「活動和演示」頁面，保留90天。
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum, and antisense oligonucleotide (ASO) platform, Solidus, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, LinkedIn and Twitter/X.
關於praxis precision medicines
praxis precision medicines是一家臨床階段的生物製藥公司，將從基因癲癇中獲得的見解轉化爲針對中樞神經系統疾病的治療，這些疾病以神經興奮與抑制失衡爲特徵。Praxis正在利用基因見解，通過我們專有的小分子平台Cerebrum和反義寡核苷酸(ASO)平台Solidus，發現和開發針對稀有以及更普遍的神經系統疾病的治療，利用我們對大腦中共享生物靶標和電路的理解。Praxis已經建立了一個多樣化的多模式中樞神經系統產品組合，包括多個運動障礙和癲癇的項目，共有四個臨床階段的候選產品。有關更多信息，請訪問並關注我們的Facebook、LinkedIn和Twitter/X。
CONTACT: Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576
聯繫方式：投資者聯繫：
praxis precision medicines
investors@praxismedicines.com
857-702-9452
媒體聯繫：
丹·費裏，電話：(617) 430-7576
生命科學顧問
Daniel@lifesciadvisors.com
617-430-7576
譯文內容由第三人軟體翻譯。
